258 related articles for article (PubMed ID: 38339280)
1. Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review.
McMahon DJ; McLaughlin R; Naidoo J
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339280
[TBL] [Abstract][Full Text] [Related]
2. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Ferrara MG; Di Noia V; D'Argento E; Vita E; Damiano P; Cannella A; Ribelli M; Pilotto S; Milella M; Tortora G; Bria E
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397295
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Berghoff AS; Bellosillo B; Caux C; de Langen A; Mazieres J; Normanno N; Preusser M; Provencio M; Rojo F; Wolf J; Zielinski CC
ESMO Open; 2019; 4(3):e000498. PubMed ID: 31297240
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.
Guaitoli G; Tiseo M; Di Maio M; Friboulet L; Facchinetti F
Transl Lung Cancer Res; 2021 Jun; 10(6):2890-2916. PubMed ID: 34295687
[TBL] [Abstract][Full Text] [Related]
5. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
6. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.
Otano I; Ucero AC; Zugazagoitia J; Paz-Ares L
Nat Rev Clin Oncol; 2023 Mar; 20(3):143-159. PubMed ID: 36639452
[TBL] [Abstract][Full Text] [Related]
7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
[TBL] [Abstract][Full Text] [Related]
9. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than
Seegobin K; Majeed U; Wiest N; Manochakian R; Lou Y; Zhao Y
Front Oncol; 2021; 11():750657. PubMed ID: 34926258
[TBL] [Abstract][Full Text] [Related]
12. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
13. Oncogene-addicted non-small cell lung cancer and immunotherapy.
Tsakonas G; Ekman S
J Thorac Dis; 2018 May; 10(Suppl 13):S1547-S1555. PubMed ID: 29951305
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
16. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
18. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
19. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
20. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
